Multi-conformation representation of Mpro identifies promising candidates for drug repurposing against COVID-19

Debarati Paul¹ · Debadrita Basu¹ · Shubhra Ghosh Dastidar¹

Received: 19 September 2020 / Accepted: 14 March 2021 / Published online: 17 April 2021

© The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2021

Abstract

The COVID-19 main protease (Mpro), one of the conserved proteins of the novel coronavirus is crucial for its replication and so is a very lucrative drug target. Till now, there is no drug molecule that has been convincingly identified as the inhibitor of the function of this protein. The current pandemic situation demands a shortcut to quickly reach to a lead compound or a drug, which may not be the best but might serve as an interim solution at least. Following this notion, the present investigation uses virtual screening to find a molecule which is already approved as a drug for some other disease but could be repurposed to inhibit Mpro. The potential of the present method of work to identify such a molecule, which otherwise would have been missed out, lies in the fact that instead of just using the crystallographically identified conformation of the receptor's ligand binding pocket, molecular dynamics generated ensemble of conformations has been used. It implicitly included the possibilities of "induced-fit" and/or "population shift" mechanisms of ligand fitting. As a result, the investigation has not only identified antiviral drugs like ribavirin, ritonavir, etc., but it has also captured a wide variety of drugs for various other diseases like amrubicin, cangrelor, desmopressin, diosmin, etc. as the potent possibilities. Some of these ligands are versatile to form stable interactions with various different conformations of the receptor and therefore have been statistically surfaced in the investigation. Overall the investigation offers a wide range of compounds for further testing to confirm their scopes of applications to combat the COVID-19 pandemic.

Keywords COVID-19 · MPro · Virtual screening · Molecular dynamics

Introduction

COVID-19, the novel coronavirus (SARS-CoV-2), a member of the class β -coronavirus, is the causal agent of the viral pneumonia outbreak 2019–2020. The recent outbreak of this highly transmissible airborne disease, first officially recorded in Wuhan, China, and thereafter in many other countries all around the world, has been declared as pandemic by WHO in March 2020. As of January 13, 2021, more than 90 million people are reported to be affected worldwide [1], and one can suspect that the actual number of affected people is more than that as many asymptomatic, yet infected people are not yet tested. As the aforesaid virus is a novel member of the family *Coronaviridae*, until now, targeted therapies against the virus are scanty.

A number of proteins are encoded by the genome of this RNA virus including 3-chymotrypsin-like protease (3CLpro) or the main protease (Mpro), RNA-dependent RNA polymerase, helicase, etc. [2]. Among these proteins, Mpro becomes a very potential drug target because of a number of reasons [3, 4]. Replication and transcription of the virus are mediated by two overlapping polyproteins pp1ab. A highly complex proteolytic processing event of the polyproteins is catalyzed by two proteases. Among the two proteases, Mpro is the key enzyme which catalyzes the cleavage of the polyproteins at 11 sites conserved in SARS-CoV and SARS-CoV2. Therefore, Mpro is essential for viral replication and is a lucrative drug target [5]. Another important feature is that though the virus is very much prone to mutations, Mpro, being a conserved protein throughout the *Coronavirinae* subfamily is much less susceptible to frequent mutation. Therefore, designing inhibitors against Mpro would be worthwhile for the treatment of not only the SARS-CoV-2 but also for the entire subfamily. Also, cleavage specificity of no human protease is known to match with that of Mpro, thereby low or no inhibitor toxicity for human proteases can be expected. The Mpro

✉ Shubhra Ghosh Dastidar
sgd@jcbosc.ac.in

¹ Division of Bioinformatics, Bose Institute, P-1/12 CIT Scheme VII M, Kolkata 700054, India

consists of 3 distinct structural domains made up of 13 β -sheets and 11 α -helices (Fig. 1) [6]. Domain1 (residues 8–101 shown in orange) and domain 2 (residues 102–184 shown in green) comprised mostly of antiparallel β -barrel, with a folding scaffold found in other viral proteases [7, 8]. Domain 3 comprising of α -helices (residues 201–306 shown in red) is specific for CoVMpro. A loop of ~15 residues (185–200 shown in purple) links domains 2 and 3. A H41–C145 catalytic dyad is present at the interface between domains 1 and 2 which hydrolyze the peptide bond at specific cleavage sites in a series of steps. Imidazole group of H41 extracts the side-chain proton of C145 resulting into thiolate nucleophile which then attacks the amide bond of the substrate. As a result of proton extraction, N-terminal portion releases from H41 which in turn releases the C-terminal portion restoring the catalytic dyad. Therefore the inhibitors which perturb the communication between the H41 and C145 would block the catalytic cycle of the protein. N3 is a computationally designed peptido-mimetic irreversible Michael acceptor inhibitor which has the capability to inhibit Mpro of not only SARS-CoV2 but also other coronaviruses, including SARS-CoV and MERS-CoV [9]. It acts as a natural target of Mpro that forms a covalent bond with the catalytic site residue like any Michael acceptor inhibitor, blocking the catalytic cycle of the protein [10]. The inhibitor also showed antiviral activity against bronchitis virus in an animal model [11]. The 50% cytotoxicity concentration of the inhibitor is >133 μ M [9].

Developing a new drug for a disease is a time-taking process. While such processes of drug development are running, there is a need of rapidly finding a rescue for the interim time. Repurposing of pre-existing drugs for the still escalating disease which took more than 1.9 million lives as of January 13, 2021, around the globe is one of such faster and more efficient approaches [12–15].

Continuous endeavor for the development of effective treatment measures by researchers worldwide has suggested some potential drugs for repurposing both in silico and experimentally. In March 2020, the WHO commenced the “SOLIDARITY Trial” of four prevailing antiviral drugs for targeting different proteins of the virus on thousands of affected people in 10 countries to estimate the treatment effects of the drugs. The drugs chloroquine and hydroxychloroquine, ritonavir/lopinavir with and without interferon-beta, and remdesivir are presently under clinical trials of different phases [16]. Additionally, a number of antibodies, antivirals, and various therapeutic compounds have been reported [2, 12–15, 17–28]. However, till date, none of these drugs or compounds can be mentioned as part of the confirmed treatment protocol for the disease.

Computer-aided drug designing (CADD) offers methods to accelerate the search for possible lead compounds, and the virtual screening of compounds with respect to a receptor is one of such widely used methods [29–33]. The standard practice of such screening is to use a conformation of the receptor as a reference to find suitable ligands that fit in its binding pocket; the model of the conformation may come either from experiment or from computation or their combination. But in a real system, in principle, all possible conformations are present, and therefore a ligand can select the conformation of the receptor that it suits, even if that is not the most probable conformation of the uncomplexed/apo receptor, and then through a population shift, the equilibrium can gradually shift towards the complex state. Therefore, the use of one conformation of the receptor, even if it is experimentally determined, can miss the ligands that would be of higher binding affinity for another conformation of the binding pocket of the receptor. To overcome this limitation, a relatively better approach is to use multiple conformations of the receptors as the references for screening the ligands. In this work,

Fig. 1 Structure of Mpro. Domain 1, orange; domain 2, green; domain3, red. Domains 2 and 3 are connected by an unstructured loop shown in purple. The catalytic site is magnified showing H41-C145 catalytic dyad

starting from the experimentally determined structure, molecular dynamic (MD) simulation-based conformational sampling has been used to generate an ensemble of conformations, and from that pool, fourteen different conformations of the receptors along with the experimentally derived receptor were chosen for the screening using the “DrugBank” database containing 2115 FDA-approved compounds [34].

Methods

Molecular dynamics simulation The uncomplexed (Apo) structure was modeled by removing the ligand N3 from the structure of the SARS-CoV-2 main protease (resolution 2.16 Å) having the PDB ID 6LU7 [9]. CHARMM36 force field [35] and parameter set were used. The system was solvated using a cubic water box of TIP3P [36] water model. K⁺ and Cl[−] ions were added to neutralize the overall charge of the system and also to maintain a 0.15 M ionic concentration. The energy minimization of the model and molecular dynamics (MD) simulation were performed using NAMD^{2.12} package [37], at 300 K, under NPT conditions, using a 2 fs time integration step, and the snapshots were saved at every 4 ps interval. Heating and equilibration were followed by production run. Short-range nonbonded interactions were truncated at 12 Å, whereas the long-range electrostatic interactions were computed using the particle mesh Ewald (PME) method [38]. The pressure and the temperature were controlled using Nosé-Hoover thermostat/barostat algorithm [39]. A 100 ns trajectory was run. Before continuing with the docking procedure, the trajectory was clustered skipping every alternate frame in UCSF Chimera based on backbone RMSD of the protein with default RMSD cutoff provided by the software [40]. Because of the relatively large population of the first 14 clusters, central frames of these clusters (named as frames 2–15) were selected. The apo crystal structure (named as frame 1) along with frames 2–15 were selected for ensemble docking. (Fig. 2, Fig. S1).

Protein preparation Apo structures, one extracted from 6LU7 and the others selected from the MD simulations, were prepared using the Protein Preparation Wizard of Schrödinger software suite 2019-1 release. Amino acid bond orders were adjusted following the addition of missing hydrogen atoms. Epik was used to calibrate the protonation as well as tautomeric states of Lys, Arg, Glu, Asp, and His to match pH 7(± 2). Finally the geometry was refined by restrained minimization with heavy atoms RMSD 0.3 Å.

Receptor grid generation A 20 Å 3D grid box of the prepared receptors was defined keeping the important catalytic residues in the center. van der Waals radius scaling and partial charge cutoff were kept default.

Ligand preparation The downloaded DrugBank database [34] and N3 ligand obtained from the complex were prepared using LigPrep without considering the protonation and ionization states. Also no stereoisomers were generated.

High-throughput virtual screening (HTVS) and docking Using the prepared receptors and the ligands from the DrugBank, rigid HTVS was done in Glide [41, 42] version 8 with default settings. Glide uses an empirical scoring function which has been parameterized for separating binders from the nonbinders in screening. The best 25% of the HTV-screened ligands were used for SP (standard precision) docking. Further, the best 25% of SP-docked ligands were taken for XP (extra precision) docking [43]. In XP docking, a more sophisticated scoring function is included so as to wipe out the false-positive results which SP docking permits.

Binding free energy calculation The free energy of ligand binding was calculated on the docked complexes using the Prime MM-GBSA method implemented in the Schrödinger software suite using default parameters. Prime MM-GBSA calculated the OPLS2005 force field-based energies of each system, using the VSGB2.0 implicit solvent model to account for the solvation energy [44].

Results and discussion

Selection of the MD frames for screening The trajectory obtained after the simulation was first visualized in VMD, and no major deviation of the protein backbone from the starting conformation was observed which was also reflected in the root-mean-square deviation (RMSD) of C α along the trajectory (Fig. S1). From the cluster of conformations, the central conformation of each of the top 14 clusters was selected for screening, in addition to the one obtained from the PDB structure itself. The C α RMSD of each selected conformation, with respect to the PDB structure (PDB ID: 6LU7), is listed in Table 1. Although the overall backbone conformation of the protein remained stable, yet in the catalytic site significant variations in the amino acids side chain orientations were noticed (Fig. 2, S2).

Noting the interactions between Mpro and N3 N3 was previously reported to interact with T24–T26, H41, M49, F140, L141, G143–C145, H163–H164, M165, E166, P168, H172, and D187–Q192 [19]. In the crystal structure, N3 has been found to form a covalent bond with C145 [9]. Re-docking of N3 in all the 15 frames using the docking pipeline crossed all of the stages; among them, frame 1, which correspond to the receptor’s conformation seen in the crystal stature, showed the best XP g-score (−7.5 kcal mol^{−1}), along with frame 2, as listed in Table 1. When frames 1 and 2 are further compared

Fig. 2 (a) Differences in the side-chain orientation of some important residues present within the catalytic site shown with some representative snapshots chosen for screening (frame 3 and 9). The conformations are distinguished by the coloring schemes; among them, the pink color refers to 6LU7. (b) and (c) Interaction of N3 with Mpro in frames 3 and 9 respectively

in terms of the binding free energy, frame 1 appeared as the best. Therefore, the positive control run successfully selected the best receptor's conformation for itself, being fully in agreement with the experimentally determined conformation. Visually, it was observed that the binding pose of N3 was similar to that of crystal structure in multiple frames, and that serves as the benchmark of the method and the capacity to identify the best pair of receptor's conformation and ligand (Fig. 3a). The g-score of the 6LU7 was used as a reference to find a ligand-drug with higher affinity. Ligand interaction diagram (Fig. 3b, c) of the re-docked complexes revealed the interaction of N3 with the catalytic dyad H41-C145 of the active site. These are the key residues for a proteolytic process where the thiol group of the C145 acts as nucleophile [45]. N3 was also found to form a hydrogen bond with N142, G143, E166, and Q189 and salt bridge with E166 in different frames (Fig. 3b, c). The salt bridge formation between N3 and Mpro is very important because E166 is known to have a crucial role

in the dimerization of Mpro by associating the binding site with dimer interface, and that is necessary for the catalytic function of the protein [31].

Shortlisting the ligands The top-scoring ligands obtained from XP docking were analyzed to find their type and strength of interactions. Such a blind screening listed 78 ligands from the entire database, which had scores better than N3 in at least one of the 15 frames of the receptor. Among them, there were a number of dyeing agents, food additives, supplements, and some nondrug molecules which were eliminated from the list; for obvious reasons, the drug molecules approved for topical application were also eliminated. This knowledge-based scrutiny yielded a shortlist of 49 compounds (Table S1, Fig. S3). Since the N3 itself showed a very similar or very close value of the dock scores in multiple frames, e.g., frames 1, 2, and 4, the short listed compounds which were present in at least 20% of the frames, i.e., 3 frames, were further identified (Table S2)

Table 1 C α RMSD (with respect to the 6LU7) of the conformations chosen for the screening. The ligand N3, as found from the crystallized complex (6LU7), was also docked to all other frames to get the reference score for all the frames

Frame index referred to in the screening	RMSD with respect to 6LU7 ($\text{\AA}$)	XP g-score of N3 (kcal mol^{-1})	Binding free energy (kcal mol^{-1})
1(6LU7)	0	-7.5	-82.4
2	1.324	-7.5	-78.9
3	0.998	-6.9	-75.7
4	1.122	-7.0	-93.2
5	1.338	-3.7	-74.8
6	0.857	-5.0	-74.5
7	1.143	-6.7	-83.1
8	0.097	-4.5	-70.6
9	1.324	-2.2	-70.0
10	1.452	-3.7	-48.2
11	1.326	-3.1	-81.4
12	1.507	-5.1	-66.1
13	1.848	-4.5	-78.4
14	2.516	-5.6	-72.8
15	2.185	-5.6	-71.4

Fig. 3 a) Superposition of N3 docked in the catalytic site in different frames. The conformations are distinguished by the coloring scheme. The crystallized conformation of the receptor is shown in pink, and that of N3 is shown in green. (b) and (c) 2D diagrams of the interactions between Mpro and N3. The residues are coloured according to their nature of sidechain: hydrophobic (green) color, positively charged (blue), negatively charged (red), other polar groups (sky blue), and glycine (white)

which resulted a list 23 compounds. In this list, 9 more compounds were added, which otherwise got eliminated due to shortfall in the number of frames in which they appeared. The reason of adding those compounds in the list was that they were biochemically and/or functionally close to one or more of those 23 compounds. For example, doxorubicin and valrubicin (Table 1, Serial no. 13 and 30, respectively) were present in 3 frames each, but three other, rubicins amrubicin, daunorubicin, and idarubicin were left out because of their presence in less number of frames; they were added in Table 2 because of their biochemical and functional similarity with doxorubicin and valrubicin.

From this list, the ligands which were present in at least 3 frames were elaborated further in with the details of their

interaction pattern with Mpro (Fig. S3). Interestingly for most of the compounds, the H-bond and salt bridge with E166 were common indicating that they might have the capability to disrupt the dimerization on Mpro which is important for performing the catalytic function [31]. A number of the screened drugs were found to interact with H41. The H-bonds and/or other interactions between H41 and different ligands could be argued to disrupt the interaction of the H41-C145 catalytic dyad rendering Mpro unable to perform its catalytic function.

Complexes from screening The Mpro, which was derived from crystal structure 6LU7 by eliminating N3, identified ritonavir as a promising drug candidate although the g-score

Table 2 Top-scoring ligands with their best XP g-score, number of frames in which they were found, and corresponding binding free energy

Serial no.	Name of drug	No. of frames where present	Highest g-score	Binding free energy in the highest-scoring frame (kcal mol ⁻¹)
1	Almasilate	6	-7.9	82.74
2	Amrubicin	2	-7.3	-74.27
3	Arbutamine	3	-8.9	-73.89
4	Cangrelor	11	-8.4	-47.83
5	Carbetocin	6	-8.0	-81.32
6	Cefixime	1	-7.8	-43.27
7	Cefpiramide	5	-8.1	-77.76
8	Ceftolozane	3	-8.9	-73.4
9	Daunorubicin	1	-6.8	-65.1
10	Desmopressin	11	-9.9	-59.36
11	Diosmin	9	-10.3	-55.58
12	Dobutamine	1	-8.2	-74.9
13	Doxorubicin	3	-7.7	-73.7
14	Droxidopa	5	-7.8	-44.7
15	Enviomycin	2	-7.8	-42.1
16	Felypressin	9	-8.9	-86.8
17	Idarubicin	1	-6.2	-56.9
18	Kanamycin	2	-7.9	-46.8
19	Lymecycline	4	-8.0	-73.31
20	Mitoxantrone	3	-9.3	-79.8
21	Novobiocin	2	-8.0	-74.3
22	Polydatin	5	-8.1	-66.0
23	Regadenoson	6	-7.7	-54.8
24	Ribavirin	4	-7.1	-29.9
25	Risedronate	6	-7.9	-21.34
26	Sofosbuvir	1	-7.3	-75.7
27	Terlipressin	3	-9.8	-84.2
28	Ritonavir	1	-7.6	-73.1
29	Tigecycline	3	-7.3	-67.2
30	Valrubicin	3	-8.1	-85.6
31	Zanamivir	1	-7.8	-46.0
32	Zoledronic acid	4	-7.7	-16.3

Fig. 5 2D ligand interaction diagram and 3D orientation of the diosmin are shown in **(a)** and **(b)** respectively for the highest scoring frame. Cation- π (red) and π - π (green) interactions among the ligand and H41

of Mpro in lowest frame 3D orientation of the ligands, and functional groups involved in the interaction are different in the highest- **(b)** and lowest **(d)**-scoring frames. Color scheme followed Fig. 1

ligand (Fig. S6e). In lowest-scoring frame in addition to H41, salt bridge was formed between the NH_3^+ group of the ligand and E166 which might have over-stabilized the ligand resulting in a low g-score (Fig. S6f). Binding free energies for all the antibiotics were in agreement with the g-scores (Table S4). The rest of the antibiotics, though with g-scores better than N3, were found in less number of frames, and therefore they were not discussed here in detail.

Among the top-scoring ligands, rubicins, the anthracycline antineoplastic antibiotics were found in 6 frames. Previous studies have reported some of the resulted rubicins to have in vitro effect to the replication of other viruses though their protease-inhibiting capacity was not clear [54–56]. These drugs along with the detail of their interactions have been listed in Table S5. Most of the drugs had g-scores greater than or very similar to N3. Among the 3 frames in which

doxorubicin was found, g-scores in frame 4 ($-7.4 \text{ kcal mol}^{-1}$) and 13 ($-7.7 \text{ kcal mol}^{-1}$) were mostly similar with the score of apo-N3 while in frame 8, it was less than N3 ($-6.4 \text{ kcal mol}^{-1}$) and it was seen in the ligand interaction diagram that in this frame, there were both cation- π and π - π interactions with H41 (Fig. S7b) while in the highest-scoring frame (frame 13), there was only π - π interaction with H41 (Fig. S7a). Also in the lowest-scoring frame, E166 was forming two H-bonds with the ligand in contrast to no H-bonds between E166 and the ligand in the highest-scoring frame. Valrubicin was found in frames 3, 7, and 13 among which scores in the first two frames were higher than N3 ($-7.7 \text{ kcal mol}^{-1}$ and $-8.1 \text{ kcal mol}^{-1}$, respectively) (Table S5). Only in the lowest-scoring frame (-5 kcal mol^{-1}) π - π interactions with H172 were found (Fig.

S7d). In both the above rubicins, binding free energies were in harmony with the respective g-scores (Table S5). Other rubicins, daunorubicin and idarubicin, were found in frame 4, but their g-scores were less than N3. Both of them were found to form salt bridges as well as H-bonds with E166 (data not shown).

One crucial reason for fatality in COVID-19 patients is venous thromboembolism [57–61]. The use of drugs that inhibit intravenous clotting like heparin and tissue plasminogen activator along with other drugs have already been disclosed as more effective [62–66]. In the present investigation, cardiovascular drugs like cangrelor and diosmin were found in more than 50% of the frames and imparted in more rigorous interactions in MD-generated receptor frames suggesting

Fig. 6 2D ligand interaction diagram and 3D orientation of cangrelor are shown in (a) and (b) respectively for the highest scoring frame, which reveal the H-bond between PO_4 group of the ligand and the catalytic site

residues. The same for the lowest scoring frame are shown in (c) and (d) which show the salt bridge between K137 and PO_4 group.. Color scheme followed Fig. 1

optimization of the complexes. Residues involved in the interactions with diosmin and cangrelor in different frames are furnished in Tables S6 and S6, respectively. Among the different plant flavonoids reported as SARS-CoV-2 inhibitor, diosmin has been reported in several studies [67–71]. In our multi-conformation-based screening study, diosmin, an anti-coagulant, was found in 9 frames, the highest and lowest being frames 10 ($-10.266 \text{ kcal mol}^{-1}$) and 6 ($-7.517 \text{ kcal mol}^{-1}$), respectively (Table S6). In the ligand interaction diagram, it was seen that there were cation- π and π - π interactions among the ligand and H41 of Mpro in the lowest frame (Fig. 5c).

Binding free energy of lowest-scoring frame was however more or less similar to that of the highest-scoring frame. The ligand orientation within the binding pocket varied in the highest and the lowest-scoring frames. L167 was forming H-bond with the ligand in the lowest-scoring frame. While g-scores of diosmin in most of the frames were more than or near the values of N3, scores of cangrelor, another cardiovascular drug, were mostly less than that of N3 (Table S7). In 2 out of 11 frames, the value was more than that of N3. H41 was found to form salt bridges with the molecule in all the frames except in the lowest one. The orientation of the ligand was

Fig. 7 2D ligand interaction diagram and 3D orientation of regadenoson are shown in (a) and (b) respectively for the highest scoring frame. The same for the lowest scoring frame are shown in (c) and (d). The higher

number of H-bonds and the involvement of $-OH$ group in case of highest scoring frame compared to the lowest scoring frame are notable. Color scheme followed Fig. 1

Fig. 8 2D ligand interaction diagram and 3D orientation of desmopressin are shown in (a) and (b) respectively for the highest-scoring frame which show that T190 and Q192 are involved in H-bonds. The same shown for

the lowest-scoring frame in (c) and (d) reveal that those H-bonds are missing. Color scheme followed Fig. 1

different in the highest and lowest-scoring frames. In the highest-scoring frame, side chains E166 and K137 were oriented towards the outer side of the catalytic side, so they were not involved in the H-bonding (Fig. 6b). The PO_4 -containing group of the ligand was forming H-bonds with the catalytic site residues. Cl^- of the ligand was also involved in the interaction in the highest-scoring frame. On the contrary, in the lowest-scoring frame, K137 was oriented towards the ligand and was forming salt bridge with the PO_4 group (Fig. 6c, d). E166 was also involved in forming H-bond with the ligand. Regadenoson was screened in 6 out of 15 frames. Details of catalytic site residues involved in the interaction with this drug

as depicted in Table S8 showed the g-scores were less than N3, the lowest and highest being -5.156 and $-7.678 \text{ kcal mol}^{-1}$, respectively. The number of H-bonds were more in the highest-scoring frame (frame 7), and the $-\text{OH}$ groups of the ligand were involved in H-bond formation (Fig. 7a) while in the lowest-scoring frame (frame 11), the $-\text{OH}$ groups were not forming H-bonds (Fig. 7c). Binding free energies of cangrelor and regadenoson were not consistent with the g-scores. It can be argued that the best pose of a ligand might not result in the lowest binding free energy as the type of interactions could alter the fitting of the ligand. Again, the poses with lowest binding free energy might be associated with over-stabilization of the ligands

Fig. 9 2D ligand interaction diagram and the 3D orientation of felypressin are shown in (a) and (b) respectively for the highest-scoring frame which reveal the H-bond and salt bridge between NH_3^+ and

E166. The same for the lowest-scoring frame are shown in (c) and (d) which find the H-bond formed between NH_2^+ and E166. Color scheme followed Fig. 1

resulting in perturbation of the optimal functionality of the ligand.

Three vasodilators desmopressin, felypressin, and terlipressin, were screened as Mpro inhibitors among which desmopressin and felypressin were found in 11 and 10 frames, respectively. Though there was no experimental evidence of antiviral effects of the pressins, felypressin has been found as an inhibitor of the dengue virus in silico [72]. Details of interactions of desmopressin and felypressin are given in Table S9 and S10, respectively. Side-chain orientations of catalytic site

residues of Mpro and also the ligand desmopressin in the highest (frame 4) and lowest (frame 11) scoring frames were different (Fig. 8). In frame 4, N119 and N142 were not involved in H-bonds while T190 and Q192 were forming H-bonds with the ligand (Fig. 8a, b). In this frame, T190 and Q192 were not oriented towards the ligand in frame 11 and thus were not involved in H-bonds formation. XP g-scores of felypressin were the highest and lowest in frames 4 and 13, respectively (Table S10). The number of H-bonds between ligand and Mpro was much higher in frame 4 especially with

E166 (Fig. 9a, c). Also salt bridges were present between E166 of Mpro and one of the NH_3^+ of the ligand in frame 4. One of the NH_2 instead of NH_3^+ was forming H-bond with E166 in frame 13, and H41 was forming H-bond with the ligand (Fig. 9b, d). The ligand was nearer to side chain of C44 in frame 13 where there was an H-bond between C44 and ligand, but in frame 4, the ligand was away from C44, and also the orientation of C44 was different. The side chains of T190 and Q192 were oriented towards the ligand in frame 4 but were away from the ligand in frame 13. As a result, H-bonds between the residues were found in frame 4 but not in frame 13 (Fig. 9b, d). In the case of the highest-scoring frame of terlipressin (frame 1), like previous two pressins, one of the NH_3^+ group of the ligand was forming H-bond as well as salt bridge with E166 (Table S11, Fig. S9a). In the lowest-scoring frame, there was no salt bridge between the ligand and Mpro (Fig. S9b). Binding free energies were in correspondence with the g-scores.

In addition to the above-discussed groups of drugs, a few drugs with different functions were found (Table 2). Some of them have been found as Mpro inhibitor in different studies [73–75]. Out of these drugs, almasilate, though found in 6 frames, is a buffering antacid; thereby, its chance of entering into the bloodstream is very less likely. Therefore, this drug has not been discussed in detail here. Also the binding free energies of the ligand were very low in different frames. Imami et al., with their transcriptome-based approach, have shown that carbetocin, the analogue of oxytocin, has an impact on the induction of immune response in COVID-19 [73]. Here, carbetocin was found as an Mpro inhibitor in 6 frames (Table S12) among which in the highest-scoring frame, the number of protein-ligand H-bonds was much more than that in other frames which might have resulted in the lowest binding free energy. Risedronate and zoledronic acid, drugs for the treatment of osteoporosis and other bone diseases, were found in 4 and 6 frames, respectively. Both of the ligands possess O^- groups which were found to be involved in the formation of salt bridge with H41 (Table S12). In the case of zoledronic acid, additionally cation- π and π - π stacking interactions with H41 were seen. The binding free energy of these ligands was very low compared to that of others ranging from ~ -2 to -21 kcalmol $^{-1}$. Polydatin, a picecid, used in various diseases like anti-arrhythmia drug and potassium channel modulator, was found as a probable Mpro inhibitor in previous studies [74, 75]. Here the ligand was found to be buried in the catalytic pocket of Mpro in the highest-scoring ligand while in the lowest-scoring one, a smaller number of residues were accessible (Table S12). Arbutamine and dobutamine, the drugs to treat cardiogenic shock, were found in frames 1 and 3, respectively. Low scoring frames of arbutamine showed covalent interactions with E166 which were not found in the highest-scoring frame. Rather in the highest-scoring frame, there was a π - π stacking interaction with H41. The binding free energy was highest in this frame. H41 of Mpro was found to form a

π - π stacking and/or cation- π interaction, and E166 was involved in salt bridge formation with droxidopa, a norepinephrine prodrug, in all frames except the highest-scoring one (frame 6). Mitoxantrone, an antineoplastic drug, was obtained in 3 frames among which a number of protein-ligand H-bonds were least in the highest-scoring frame (Table S12). The binding free energies of droxidopa and mitoxantrone were in harmony with the g-scores. It can be stated that more protein-ligand interaction might sometimes result in over-stabilization of the ligands which might alter the optimal function of the ligand. Some of the drugs discussed in this paragraph were detected as an inhibitor of Mpro in previous studies, most of them being in silico. These drugs could be tested further experimentally. Modification of functional groups of the rest of the drugs might result into new compounds with the capability to inhibit Mpro.

The dock score of N3 was taken as reference, which is experimentally known to bind to Mpro and used it to shortlist the hits with scores better than N3. This was done with the expectation that it would be able to identify the ligand at least having similar interaction pattern with desired biochemical activity and then would carry some additional features that might increase the probability of success rate of the prediction. The present virtual screening and MM-GBSA-based approaches have revealed a number of FDA-approved drugs which have Mpro affinity above the cutoff of N3 scores. Almost all the top-scoring drugs were forming hydrogen bonds with the catalytic site residues H41, M49, F140, L141, G143-C145, H163–164, M165, E166, P168, H172, and D187-N192, the same contact points seen in the N3 complex. Though not all, some of the identified drugs have already proven antiviral effects.

Variation in the g-scores and binding free energy for the same ligand in different frames were due to differences in the interactions and packing of the ligand inside the catalytic site. There have been some exceptions in the trends of the g-scores and the binding free energies, which otherwise reflected the correlation in their trends, i.e., the good g-score did not correspond to promising binding affinity in some cases which indicated the need of some advanced method of refinement. But in this work, shortlisting of ligands by either of the scoring methods was the goal, and as that was achieved, the strict match between g-score and binding free energy was not aspired. Again the consonance of binding free energy with the g-score in most of the ligands has confirmed that the particular pattern of interaction in the best scoring ligands resulted in the lowest binding free energies. Also, it was evident that the usage of multiple conformations for screening resulted in some molecules which might have been rejected if a single conformation would have been used because of relatively lower g-score and binding free energy.

Conclusions

A list of FDA-approved drugs have been obtained through virtual screening with the promise to inhibit Mpro of COVID-19. The N3 molecule is already known to bind to Mpro, which is reported as its co-crystallized ligand. The binding score of N3 has been used as a reference, and the ligands with scores better than this are plausibly expected to bind to Mpro with higher affinity. The scores of the docking and also the computed binding free energies are best interpreted in a relative scale, instead of debating on the absolute values. The use of ensemble representation of the receptor's conformation has implicitly covered the possibilities of "induced-fit" and/or "population shift" mechanisms that the ligands might adapt to fit in the pocket, and therefore this method has been powerful to identify a wide variety of ligands, and many of which would have been otherwise missed out. It has not only identified antiviral drugs like ribavirin, ritonavir, etc., but it has also identified the drugs used in various other diseases, e.g., amrubicin, cangrelor, desmopressin, diosmin, etc. as the potential candidates to inhibit Mpro. The screened drugs might have a cumulative inhibitory effect on the viral multiplication and pathogenesis. Functional group modification of the drugs might lead to better binding affinity with Mpro. Top-scoring ligands with correlating binding free energies could be considered for persuasion of further tests and designing inhibitors against the viral protein.

Supplementary Information The online version contains supplementary material available at <https://doi.org/10.1007/s00894-021-04732-1>.

Acknowledgements DP thanks the Council of Scientific and Industrial Research (CSIR), Government of India, and DB thanks Department of Biotechnology (DBT), Government of India, for funding. DP thanks Schrödinger Inc. for extending support during the revision of the manuscript.

Author contribution DB carried out the MD simulation of MPro. DP carried out the virtual screening, docking, and all subsequent analyzes in the ligand selection pipeline including free energy calculations. DP wrote the major part of the manuscript and prepared the illustrations. DB took part in the text editing and prepared some illustrations. SGD advised the overall project and substantially edited the manuscript.

Availability of data and material The size of the dataset being huge; it cannot be uploaded easily. Therefore, it would be made available on request.

Code availability Most of the work is done with licensed software therefore those are not transferable. Other scripts written in the group could be made available on request.

Declarations

Conflict of interest The authors declare no competing interests.

References

1. Coronavirus Update (Live): 30,235,321 Cases and 948,335 Deaths from COVID-19 Virus Pandemic - Worldometer. <https://www.worldometers.info/coronavirus/>
2. Strodel B, Olubiyi O, Olagunju M et al (2020) High Throughput Virtual Screening to Discover Inhibitors of the Main Protease of the Coronavirus SARS-CoV-2. *Molecules*. 25(14):3193
3. Yang H, Bartlam M, Rao Z (2006) Drug design targeting the main protease, the Achilles heel of coronaviruses. *Curr Pharm Des* 12: 4573–4590
4. Anand K, Yang H, Bartlam M, Rao Z, Hilgenfeld R (2005) Coronavirus main proteinase: target for antiviral drug therapy. In: Schmidt A., Weber O., Wolff M.H. (eds) *Coronaviruses with Special Emphasis on First Insights Concerning SARS*. Birkhäuser Advances in Infectious Diseases BAID. Birkhäuser Basel. https://doi.org/10.1007/3-7643-7339-3_9
5. Świderek K, Moliner V (2020) Revealing the molecular mechanisms of proteolysis of SARS-CoV-2 M^{pro} by QM/MM computational methods. *Chem Sci* 11:10626–10630
6. Chang G-G (2009) Quaternary structure of the SARS coronavirus main protease. *Mol Biol SARS-Coronavirus*:115–128
7. Hegyi A, Friebe A, Gorbalenya AE, Ziebuhr J (2002) Mutational analysis of the active centre of coronavirus 3C-like proteases. *J Gen Virol* 83:581–593
8. Anand K (2002) Structure of coronavirus main proteinase reveals combination of a chymotrypsin fold with an extra alpha-helical domain. *EMBO J* 21:3213–3224
9. Jin Z, Du X, Xu Y et al (2020) Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors. *Nature* 582:289–293
10. Griffin JWD (2020) SARS-CoV and SARS-CoV-2 main protease residue interaction networks change when bound to inhibitor N3. *J Struct Biol* 211:107575
11. Xue X, Yu H, Yang H et al (2008) Structures of two coronavirus Main proteases: implications for substrate binding and antiviral drug design. *J Virol* 82:2515–2527
12. Elmezayen AD, Al-Obaidi A, Şahin AT, Yelekçi K (2020) Drug repurposing for coronavirus (COVID-19): *in silico* screening of known drugs against coronavirus 3CL hydrolase and protease enzymes. *J Biomol Struct Dyn*. <https://doi.org/10.1080/07391102.2020.1758791>
13. Senanayake SL (2020) Drug repurposing strategies for COVID-19. *Future Drug Discov* 2:fdd-2020-0010. <https://doi.org/10.4155/fdd-2020-0010>
14. Koulgi S, Jani V, Uppuladinne M, Sonavane U, Nath AK, Darbari H, Joshi R (2020) Drug repurposing studies targeting SARS-CoV-2: an ensemble docking approach on drug target 3C-like protease (3CL^{pro}). *J Biomol Struct Dyn*. <https://doi.org/10.1080/07391102.2020.1792344>
15. Liu C, Zhou Q, Li Y et al (2020) Research and development on therapeutic agents and vaccines for COVID-19 and related human coronavirus diseases. *ACS Cent Sci* 6:315–331
16. Kupferschmidt K, CohenMar. 22 J, 2020, Pm 3:28 (2020) WHO launches global megatrial of the four most promising coronavirus treatments. In: Sci. AAAS. <https://www.sciencemag.org/news/2020/03/who-launches-global-megatrial-four-most-promising-coronavirus-treatments>
17. Gordon DE, Jang GM, Bouhaddou M et al (2020) A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. *Nature* 583:459–468
18. Anand K, Ziebuhr J, Wadhwani P et al (2003) Coronavirus main proteinase (3CL^{pro}) structure: basis for design of anti-SARS. *Drugs, Science* 300:1763–7

19. Wang J (2020) Fast identification of possible drug treatment of coronavirus disease-19 (COVID-19) through computational drug repurposing study. *J Chem Inf Model* 60:3277–3286
20. Cava C, Bertoli G, Castiglioni I (2020) In silico discovery of candidate drugs against Covid-19. *Viruses* 12:404
21. Chandel V, Raj S, Rath B, Kumar D (2020) In silico identification of potent FDA approved drugs against coronavirus COVID-19 main protease: a drug repurposing approach. *Chem Biol Lett* 7: 166–175
22. Cuesta SA, Mora JR, Márquez EA (2021) In Silico Screening of the DrugBank Database to Search for Possible Drugs against SARS-CoV-2. *Molecules* 26:1100
23. Ibrahim MAA, Abdelrahman AHM, Allemailem KS et al (2021) In Silico Evaluation of Prospective Anti-COVID-19 Drug Candidates as Potential SARS-CoV-2 Main Protease Inhibitors. *Protein J* 2:1–14. <https://doi.org/10.1007/s10930-020-09945-6>
24. Madhusoodanan J (2020) News feature: to counter the pandemic, clinicians bank on repurposed drugs. *Proc Natl Acad Sci* 117: 10616–10620
25. Huynh T, Wang H, Luan B (2020) *In silico* exploration of the molecular mechanism of clinically oriented drugs for possibly inhibiting SARS-CoV-2's main protease. *J Phys Chem Lett* 11: 4413–4420
26. Gil C, Ginex T, Maestro I et al (2020) COVID-19: drug targets and potential treatments. *J Med Chem* 63:12359–12386
27. Joshi RS, Jagdale SS, Bansode SB, et al (2020) Discovery of potential multi-target-directed ligands by targeting host-specific SARS-CoV-2 structurally conserved main protease. *J Biomol Struct Dyn* 1–16. <https://doi.org/10.1080/07391102.2020.1760137>
28. Ullrich S, Nitsche C (2020) The SARS-CoV-2 main protease as drug target. *Bioorg Med Chem Lett* 30:127377
29. Shaikh F, Zhao Y, Alvarez L et al (2019) Structure-based in silico screening identifies a potent ebolavirus inhibitor from a traditional Chinese medicine library. *J Med Chem* 62:2928–2937
30. Vora J, Patel S, Sinha S et al (2019) Structure based virtual screening, 3D-QSAR, molecular dynamics and ADMET studies for selection of natural inhibitors against structural and non-structural targets of chikungunya. *J Biomol Struct Dyn* 37:3150–3161
31. Watanabe K, Ishikawa T, Otaki H et al (2017) Structure-based drug discovery for combating influenza virus by targeting the PA–PB1 interaction. *Sci Rep* 7:9500
32. Shechter S, Thomas DR, Lundberg L et al (2017) Novel inhibitors targeting venezuelan equine encephalitis virus capsid protein identified using in silico structure-based-drug-design. *Sci Rep* 7:17705
33. Krishnan DA, Sangeetha G, Vajravijayan S et al (2020) Structure-based drug designing towards the identification of potential antiviral for COVID-19 by targeting endoribonuclease NSP15. *Inform Med Unlocked* 20:100392
34. Wishart DS, Knox C, Guo AC et al (2008) DrugBank: a knowledgebase for drugs, drug actions and drug targets. *Nucleic Acids Res* 36:D901–D906
35. Huang J, MacKerell AD (2013) CHARMM36 all-atom additive protein force field: validation based on comparison to NMR data. *J Comput Chem* 34:2135–2145
36. Jorgensen WL, Chandrasekhar J, Madura JD et al (1983) Comparison of simple potential functions for simulating liquid water. *J Chem Phys* 79:926–935
37. Phillips JC, Braun R, Wang W et al (2005) Scalable molecular dynamics with NAMD. *J Comput Chem* 26:1781–1802
38. Darden T, Perera L, Li L, Pedersen L (1999) New tricks for modelers from the crystallography toolkit: the particle mesh Ewald algorithm and its use in nucleic acid simulations. *Structure* 7:R55–R60
39. Nosé S (1984) A unified formulation of the constant temperature molecular dynamics methods. *J Chem Phys* 81:511–519. <https://doi.org/10.1063/1.447334>
40. Pettersen EF, Goddard TD, Huang CC et al (2004) UCSF chimera—a visualization system for exploratory research and analysis. *J Comput Chem* 25:1605–1612
41. Friesner RA, Banks JL, Murphy RB et al (2004) Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. *J Med Chem* 47:1739–1749
42. Halgren TA, Murphy RB, Friesner RA et al (2004) Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. *J Med Chem* 47:1750–1759
43. Friesner RA, Murphy RB, Repasky MP et al (2006) Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein–ligand complexes. *J Med Chem* 49:6177–6196
44. Li J, Abel R, Zhu K et al (2011) The VSGB 2.0 model: a next generation energy model for high resolution protein structure modeling. *Proteins Struct Funct Bioinform* 79:2794–2812
45. Xue X, Yang H, Shen W et al (2007) Production of authentic SARS-CoV Mpro with enhanced activity: application as a novel tag-cleavage endopeptidase for protein overproduction. *J Mol Biol* 366:965–975
46. Chen J, Xia L, Liu L et al (2020) Antiviral activity and safety of darunavir/cobicistat for the treatment of COVID-19. *Open Forum Infect Dis* 7:ofaa241. <https://doi.org/10.1093/ofid/ofaa241>
47. Khalili JS, Zhu H, Mak NSA et al (2020) Novel coronavirus treatment with ribavirin: groundwork for an evaluation concerning COVID-19. *J Med Virol* 92:740–746
48. Ghahremanpour Mohammad M, Tirado-Rives Julian, Deshmukh Maya, Ippolito Joseph A, Zhang Chun-Hui, Cabeza Israel, de Vaca Maria-Elena, Liosi Karen S, Anderson, and William L. Jorgensen, (2020) Identification of 14 Known Drugs as Inhibitors of the Main Protease of SARS-CoV-2 ACS. *Med Chem Lett* 11: 2526–2533
49. Tan ELC, Ooi EE, Lin C-Y et al (2004) Inhibition of SARS coronavirus infection in vitro with clinically approved antiviral drugs. *Emerg Infect Dis* 10:581–586
50. Hall DC, Ji H-F (2020) A search for medications to treat COVID-19 via in silico molecular docking models of the SARS-CoV-2 spike glycoprotein and 3CL protease. *Travel Med Infect Dis* 35:101646. <https://doi.org/10.1016/j.tmaid.2020.101646>
51. Martiniano B, Alberto M-M, Irving B-R (2020) Identification of saquinavir as a potent inhibitor of dimeric SARS-CoV2 main protease through MM/GBSA. *J Mol Model* 26:340
52. Colson P, Raoult D (2016) Fighting viruses with antibiotics: an overlooked path. *Int J Antimicrob Agents* 48:349–352
53. Damle B, Vourvachis M, Wang E et al (2020) Clinical pharmacology perspectives on the antiviral activity of azithromycin and use in COVID-19. *Clin Pharmacol Ther* 108:201–211
54. Kaptein SJF, De Burghgraef T, Froeyen M et al (2010) A derivative of the antibiotic doxorubicin is a selective inhibitor of dengue and yellow fever virus replication in vitro. *Antimicrob Agents Chemother* 54:5269–5280
55. Imai H, Dansako H, Ueda Y et al (2018) Daunorubicin, a topoisomerase II poison, suppresses viral production of hepatitis B virus by inducing cGAS-dependent innate immune response. *Biochem Biophys Res Commun* 504:672–678
56. Hou H-Y, Lu W-W, Wu K-Y et al (2016) Idarubicin is a broad-spectrum enterovirus replication inhibitor that selectively targets the virus internal ribosomal entry site. *J Gen Virol* 97:1122–1133
57. Khan IH, Savarimuthu S, Leung MST, Harky A (2020) The need to manage the risk of thromboembolism in COVID-19 patients. *J Vasc Surg* 72:799–804
58. Cavalcanti DD, Raz E, Shapiro M et al (2020) Cerebral venous thrombosis associated with COVID-19. *Am J Neuroradiol* 41: 1370–1376
59. Vinayagam S, Sattu K (2020) SARS-CoV-2 and coagulation disorders in different organs. *Life Sci* 260:118431

60. Wichmann D (2020) Autopsy Findings and Venous Thromboembolism in Patients With COVID-19. *Ann Intern Med* 173:1030
61. Lemke G, Silverman GJ (2020) Blood clots and TAM receptor signalling in COVID-19 pathogenesis. *Nat Rev Immunol* 20:395–396
62. Goyal A, Saigal S, Niwariya Y et al (2021) Successful use of tPA for thrombolysis in COVID related ARDS: a case series. *J Thromb Thrombolysis* 51:293–296
63. Wang J, Hajizadeh N, Moore EE, et al (2020) Tissue plasminogen activator (tPA) treatment for COVID-19 associated acute respiratory distress syndrome (ARDS): A case series. *J Thromb Haemost* 18: 1752–1755
64. Elissa Driggin, Mahesh Madhavan, Behnood Bikdeli, Sahil A. Parikh (2020) Prophylaxis and Treatment of Venous Thromboembolic Disease in COVID-19. In: *Am. Coll. Cardiol.* <https://www.acc.org/latest-in-cardiology/articles/2020/06/12/08/16/prophylaxis-and-treatment-of-venous-thromboembolic-disease-in-covid-19>
65. Bikdeli B, Madhavan MV, Jimenez D et al (2020) COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up. *J Am Coll Cardiol* 75:2950–2973
66. Moores LK, Tritschler T, Brosnahan S et al (2020) Prevention, Diagnosis, and Treatment of VTE in Patients With Coronavirus Disease 2019. *Chest* 158:1143–1163
67. Jo S, Kim S, Shin DH, Kim MS (2020) Inhibition of SARS-CoV 3CL protease by flavonoids. *J Enzyme Inhib Med Chem* 35:145–151
68. Coppola M, Mondola R. (2020) Potential Unconventional Medicines for the Treatment of SARS-CoV-2. *Drug Res (Stuttg)* 70:286
69. Meneguzzo F, Ciriminna R, Zabini F, Pagliaro M (2020) Review of Evidence Available on Hesperidin-Rich Products as Potential Tools against COVID-19 and Hydrodynamic Cavitation-Based Extraction as a Method of Increasing Their Production. *Processes* 8:549. <https://doi.org/10.3390/pr8050549>
70. Haggag Yusuf A et al (2020) Is Hesperidin Essential for Prophylaxis and Treatment of COVID-19 Infection? *Med Hypotheses* 144:109957
71. Thakur L, Vadhera P, Yadav N (2020) Combating Sars-Cov-19 By Phytochemicals: An In Silico Study. *Innovare Journal of Life Sciences* 8:1–4
72. Nasution Aini, Tambunan. (2017) Virtual screening of commercial cyclic peptides as NS2B-NS3 protease inhibitor of dengue virus serotype 2 through molecular docking simulation. *IOP Conf Series: Materials Science and Engineering*; 188: 012017
73. Imami AS, O'Donovan SM, Creeden JF et al (2020) Oxytocin's anti-inflammatory and proimmune functions in COVID-19: a transcriptomic signature-based approach. *Physiol Genomics* 52: 401–407
74. Bonucci M, Raggi R, Vacca RA (2020) Polydatin and its potential protective effect on COVID-19. *Clin Nutr* 39:3850–3851
75. Lo Muzio L, Bizzoca ME, Ravagnan G (2020) New intriguing possibility for prevention of coronavirus pneumonitis: Natural purified polyphenols. *Oral Dis.* <https://doi.org/10.1111/odi.13518>

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.